JGC
CAPR icon

J. Goldman & Co’s Capricor Therapeutics CAPR Stock Holding History

J. Goldman & Co’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.5M Sell
541,522
-53,854
-9% -$1.43M 0.48% 54
2025
Q4 		$17.2M Buy
595,376
+113,395
+24% +$1.48M 0.45% 58
2025
Q3 		$3.48M Buy
+481,981
New +$3.55M 0.09% 234

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

J. Goldman & Co's CAPR Position: Q1 2026 in Review

J. Goldman & Co reduced its Capricor Therapeutics (CAPR) stake by 9% in Q1 2026, selling an estimated $1.43M and leaving 541,522 shares worth $16.5M. The position accounts for 0.48% of the portfolio, ranked #54.

J. Goldman & Co first reported a position in CAPR in Q3 2025 and has held it in 3 quarters since. The position peaked at $17.2M in Q4 2025. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • J. Goldman & Co held 541,522 shares of Capricor Therapeutics worth $16.5M as of Q1 2026.
  • J. Goldman & Co sold 53,854 Capricor Therapeutics shares in Q1 2026, an estimated $1.43M.
  • Capricor Therapeutics made up 0.48% of J. Goldman & Co's portfolio in Q1 2026, its #54 holding.
  • J. Goldman & Co first reported a position in Capricor Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • J. Goldman & Co's Capricor Therapeutics position peaked at $17.2M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.